Natixis Advisors LLC Purchases 10,692 Shares of Repligen Co. (NASDAQ:RGEN)

Natixis Advisors LLC boosted its position in Repligen Co. (NASDAQ:RGEN) by 31.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,317 shares of the biotechnology company’s stock after buying an additional 10,692 shares during the period. Natixis Advisors LLC owned approximately 0.08% of Repligen worth $6,379,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RGEN. Resources Management Corp CT ADV bought a new stake in Repligen in the 3rd quarter valued at about $37,000. Quarry LP increased its position in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. boosted its stake in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Global Retirement Partners LLC boosted its stake in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 129 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Trading Up 0.5 %

NASDAQ:RGEN opened at $140.02 on Friday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.84 billion, a PE ratio of -274.55, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The firm’s 50 day moving average is $156.18 and its 200 day moving average is $148.32. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $200.03.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Margaret Pax purchased 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on RGEN. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group lifted their price target on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Evercore ISI began coverage on Repligen in a research note on Tuesday. They set an “in-line” rating and a $155.00 price target for the company. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.